Academic Journal
A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients
| العنوان: | A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients |
|---|---|
| المؤلفون: | Tomiyama, Takahiro, Suzuki, Rigel, Harada, Noboru, Tamura, Tomokazu, Toshida, Katsuya, Kosai-Fujimoto, Yukiko-, Tomino, Takahiro, Yoshiya, Shohei, Nagao, Yoshihiro, Takeishi, Kazuki, Itoh, Shinji, Kobayashi, Nobuhiro, Ito, Hayato, Yoshio, Sachiyo, Kanto, Tatsuya, Yoshizumi, Tomoharu, Fukuhara, Takasuke |
| المساهمون: | Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development |
| المصدر: | Frontiers in Cellular and Infection Microbiology ; volume 13 ; ISSN 2235-2988 |
| بيانات النشر: | Frontiers Media SA |
| سنة النشر: | 2023 |
| المجموعة: | Frontiers (Publisher - via CrossRef) |
| الوصف: | Introduction We examined the neutralizing antibody production efficiency of the second and third severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine doses (2 nd - and 3 rd -dose) and neutralizing activity on mutant strains, including, the Ancestral, Beta and Omicron strains using green fluorescent protein-carrying recombinant SARS-CoV-2, in living-donor liver transplantation (LDLT) recipients. Methods The patients who were administered vaccines other than Pfizer- BioNTechBNT162b2 and who had coronavirus disease 2019 in this study period were excluded. We enrolled 154 LDLT recipients and 50 healthy controls. Result The median time were 21 days (between 1 st and 2 nd vaccination) and 244 days (between 2 nd and 3 rd vaccination). The median neutralizing antibody titer after 2 nd -dose was lower in LDLT recipients than in controls (0.46 vs 1.00, P<0.0001). All controls had SARS-CoV-2 neutralizing antibodies, whereas 39 LDLT recipients (25.3%) had no neutralizing antibodies after 2 nd -dose; age at vaccination, presence of ascites, multiple immunosuppressive treatments, and mycophenolate mofetil treatment were significant risk factors for nonresponder. The neutralizing activities of recipient sera were approximately 3-fold and 5-fold lower than those of control sera against the Ancestral and Beta strains, respectively. The median antibody titer after 3 rd -dose was not significantly different between recipients and controls (1.02 vs 1.22, p=0.0758); only 5% recipients was non-responder. The neutralizing activity after third dose to Omicron strains were enhanced and had no significant difference between two groups. Conclusion Only the 2nd-dose was not sufficiently effective in recipients; however, 3rd-dose had sufficient neutralizing activity against the mutant strain and was as effective as that in healthy controls. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| DOI: | 10.3389/fcimb.2023.1197349 |
| DOI: | 10.3389/fcimb.2023.1197349/full |
| الاتاحة: | http://dx.doi.org/10.3389/fcimb.2023.1197349 https://www.frontiersin.org/articles/10.3389/fcimb.2023.1197349/full |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| رقم الانضمام: | edsbas.92908662 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3389/fcimb.2023.1197349 |
|---|